Dr. Lal PathLabs Share Price Gains Over 4% After Q2 FY27 Earnings Results: Total Income Up 20.2% YoY

On November 4, 2026, Dr. Lal PathLabs Limited released its unaudited consolidated financial results for the quarter and half year ended September 30, 2026, as per the exchange filings. 

Dr. Lal PathLabs Q2 FY27 Earnings Results 

The exchange reported a 20.2% year-on-year (YoY) increase in total income for the September 2026 quarter, reaching ₹908.20 crore. However, this represents a 9.5% increase quarter-on-quarter (QoQ) from ₹829.60 crore in the June 2026 quarter. 

 Net profit for the same period rose 27.4% YoY to ₹193.90 crore, though it increased by 13.7% QoQ from ₹170.50 crore in June 2026. 

Half-Yearly Financial Performance 

For the half year ended September 30, 2026, Dr. Lal PathLabs Limited's total income increased by 19.6% YoY to ₹1,737.80 crore, compared to ₹1,453.30 crore in the previous year.  

Net profit (PAT) for this period rose by 27.3% YoY to ₹364.40 crore, up from ₹286.20 crore in the corresponding period of the previous year. 

Operational EBITDA and Cash Structure 

Consolidated EBITDA for the quarter rose by 25.1% to ₹280 crore, maintaining a strong margin profile of 32.1%. Half-yearly EBITDA climbed to ₹528 crore with a 31.6% margin.  

The company accumulated substantial financial liquidity, reporting cash and cash equivalents of ₹1,746 crore as of September 30, 2026. Total operating expenses for the second quarter were effectively contained at ₹594 crore. 

Strategic Corporate Developments & Interim Dividend 

The Board of Directors has approved and declared a 2nd Interim Dividend of INR 5/- per equity share (@ 50% on a face value of INR 10/- each) for the financial year 2026-27.  

The record date for the purpose of payment of this 2nd Interim Dividend shall be November 11, 2026. The 2nd Interim Dividend will be completely distributed within 30 days of its formal declaration date. 

Diagnostic Network and Healthcare Infrastructure 

Dr. Lal PathLabs operates a highly comprehensive nationwide diagnostic network across India to provide optimal patient core testing. Their expansive corporate infrastructure serves individual patients, corporate entities, hospitals, and third-party medical providers. 

As of March 31, 2026, the scaling clinical network includes 312 dedicated clinical laboratories, 7,727 dynamic patient service centers, and 13,935 distinct pick-up points to ensure seamless healthcare delivery logistics. 

Read More: NTPC Share Price Gains Over 2% Post Q2 Earnings Results: Total Income Up 20.9% YoY! 

Dr. Lal PathLabs Share Price Performance  

As of November 04, 2026, at 2:59 PM, Dr. Lal PathLabs share price on NSE was trading at ₹2,003.30 up by 4.03% from the previous closing price. 

Conclusion 

Dr. Lal PathLabs Limited's operational matrix for Q2 FY27 showcases strong resilience, marked by a 20.2% YoY surge in total income to ₹908.20 crore alongside high structural efficiency delivering ₹193.90 crore in PAT. A strong liquidity backstop of ₹1,746 crore in cash positions the network safely for infrastructure scaling throughout upcoming quarters. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.    

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.